{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:45:37Z","timestamp":1768279537085,"version":"3.49.0"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T00:00:00Z","timestamp":1352851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0049908","type":"journal-article","created":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T17:31:25Z","timestamp":1352914285000},"page":"e49908","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Observational Study of the Association of First Insulin Type in Uncontrolled Type 2 Diabetes with Macrovascular and Microvascular Disease"],"prefix":"10.1371","volume":"7","author":[{"given":"Gillian C.","family":"Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex D.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip D.","family":"Home","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,11,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.107.720847","article-title":"Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people","volume":"117","author":"TK Schramm","year":"2008","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"A Wright","year":"2002","journal-title":"Diabetes Care"},{"key":"ref3","unstructured":"National Institute for Health and Clinical Excellence (2009) Type 2 diabetes: newer agents. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG87ShortGuideline.pdf\" xlink:type=\"simple\">http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG87ShortGuideline.pdf<\/ext-link>. Accessed 2010 Sep 1."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"RR Holman","year":"2007","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The Treat-to-Target Trial","volume":"26","author":"MC Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00125-009-1415-7","article-title":"Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study","volume":"52","author":"J Rosenstock","year":"2009","journal-title":"Diabetologia"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"The ORIGIN Trial Investigators (2012) Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine 10.1056\/NEJMoa1203858.","DOI":"10.1056\/NEJMoa1203858"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1335","article-title":"Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research","volume":"16","author":"JD Lewis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref9","unstructured":"NHS Centre for Coding and Classification (1996) The READ Codes Version 3. London: Stationary Office."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/pds.2345","article-title":"Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study","volume":"21","author":"GC Hall","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref11","unstructured":"Joint Formulary Committee (2008) British National Formulary 55. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.bnf.org\/bnf\/\" xlink:type=\"simple\">http:\/\/www.bnf.org\/bnf\/<\/ext-link>. Accessed 2008 Mar 1."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"AS Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"AS Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"b1870","DOI":"10.1136\/bmj.b1870","article-title":"Effect of the quality and outcomes framework on diabetes care in the United Kingdom: retrospective cohort study","volume":"338","author":"M Calvert","year":"2009","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"RR Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"MC Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes","volume":"28","author":"HU Janka","year":"2005","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"H Yki-Jarvinen","year":"2006","journal-title":"Diabetologia"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","article-title":"Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial","volume":"371","author":"RG Bretzel","year":"2008","journal-title":"Lancet"},{"key":"ref20","first-page":"380","article-title":"Beginning insulin in people with type 2 diabetes mellitus in real life practice \u2212 1-year results of the 4-year CREDIT Study Diabetologia","volume":"53","author":"P Home","year":"2010"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/pds.1686","article-title":"Validation of death and suicide recording on the THIN UK primary care database","volume":"18","author":"GC Hall","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0049908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T12:51:56Z","timestamp":1562331116000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0049908"}},"subtitle":[],"editor":[{"given":"Xin-Liang","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,14]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0049908","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,14]]}}}